Latest news with #OtsukaPharma
Reuters
18-07-2025
- Health
- Reuters
US FDA advisers recommend against Otsuka's PTSD combination treatment
July 18 (Reuters) - The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's (4578.T), opens new tab antipsychotic drug in combination with Viatris' (VTRS.O), opens new tab antidepressant Zoloft for treating adults with PTSD. The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft, chemically known as sertraline, for treating the condition. Its decision is in line with the FDA staff reviewers' assessment on Wednesday. Otsuka's application was based on the data from one mid-stage and two late-stage studies testing the combination treatment compared to sertraline plus placebo. It had failed to meet the main goal of significantly reducing severity of PTSD symptoms in one of the late-stage studies compared to sertraline and placebo. PTSD, a disorder caused by very stressful events, affects about 4% of U.S. adults and is commonly associated with war veterans. But natural disasters, abuse or other trauma may also trigger the condition in civilians. "We simply cannot negate one negative study and say we are going to approve based on two other positive studies," said panelist Pamela Shaw, biostatistician at Kaiser Permanente. Otsuka did not immediately respond to a Reuters request for comment. The advisers discussed possible side-effects such as weight gain and movement disorders associated with long-term use of antipsychotics, but noted that the combination may be a better treatment option for patients who respond poorly to sertraline alone. "The big question for me is knowing that antipsychotics can cause real problems, especially with long-term use, and the modest benefit that the combination treatment potentially can offer," said panelist Walter Dunn, assistant clinical professor of psychiatry at university of California Los Angeles. The FDA, originally set to decide on the company's application by February 8, delayed its decision to seek the advisory panel's input. The agency has not set a new action date for the drug. The health regulator typically follows the advice of its expert advisers, but is not required to do so. If approved, the combination drug would be the first PTSD treatment to gain U.S. nod in more than two decades after Zoloft and GSK's (GSK.L), opens new tab Paxil. Brexpiprazole, branded as Rexulti, is approved in the U.S. to treat agitation in patients with Alzheimer's disease as well as for adults with major depressive disorder and schizophrenia. The drug is being co-developed by Otsuka and Danish drugmaker Lundbeck ( opens new tab.
Reuters
18-07-2025
- Health
- Reuters
US FDA advisers vote against Otsuka's PTSD combination treatment
July 18 (Reuters) - The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's (4578.T), opens new tab drug when used in combination with Viatris' (VTRS.O), opens new tab Zoloft for the treatment of adults with PTSD. The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft for treating the condition. PTSD, a disorder caused by very stressful events, affects about 4% of U.S. adults and is commonly associated with war veterans. But natural disasters, abuse or other trauma may also trigger the condition in civilians. The recommendation comes after the FDA's staff reviewers on Wednesday raised efficacy concerns over the use of the combination therapy, citing inconsistent trial results and a modest treatment effect.
Yahoo
18-07-2025
- Health
- Yahoo
US FDA advisers vote against Otsuka's PTSD combination treatment
(Reuters) -The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's drug when used in combination with Viatris' Zoloft for the treatment of adults with PTSD. The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft for treating the condition. PTSD, a disorder caused by very stressful events, affects about 4% of U.S. adults and is commonly associated with war veterans. But natural disasters, abuse or other trauma may also trigger the condition in civilians. The recommendation comes after the FDA's staff reviewers on Wednesday raised efficacy concerns over the use of the combination therapy, citing inconsistent trial results and a modest treatment effect. Solve the daily Crossword
Reuters
16-07-2025
- Health
- Reuters
FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment
July 16 (Reuters) - The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's (4578.T), opens new tab drug in combination with Viatris' (VTRS.O), opens new tab Zoloft for the treatment of adults with PTSD. The FDA staff's assessment comes ahead of a meeting of its independent experts on Friday, who will make recommendations on whether the regulator should approve the use of the drug, brexpiprazole, in combination with Zoloft for treating PTSD. The FDA staff cited inconsistent trial results and a modest treatment effect that may not be clinically meaningful as reasons for the efficacy concerns. Otsuka's application was based on the data from one mid-stage and two late-stage studies testing the combination of brexpiprazole and Zoloft in PTSD patients compared to sertraline monotherapy. The reviewers, however, noted that one of the late-stage studies failed to show statistically significant differences in treatment response between the two groups. They also added that the mid-stage study had statistical and methodological concerns. PTSD is a mental health condition that can develop after a traumatic event, causing symptoms including flashbacks, nightmares and severe anxiety. Brexpiprazole, sold under the brand name of Rexulti, is approved in the U.S. to treat agitation in patients with Alzheimer's disease as well as for adults with major depressive disorder and schizophrenia. The drug is being co-developed by Otsuka and Danish drugmaker Lundbeck ( opens new tab. Otsuka had said earlier this year the FDA, which was originally set to decide on the company's treatment by February 8, delayed its decision to seek the advisory panel's input on certain issues related to the marketing application. The agency has not set a new action date for the drug. If approved, the combination drug would be the first PTSD treatment to gain U.S. approval in over 30 years after Zoloft and GSK's (GSK.L), opens new tab Paxil.
